{"id":"bisphosphonates-combined-with-vancomycin","safety":{"commonSideEffects":[{"rate":null,"effect":"Nephrotoxicity (vancomycin)"},{"rate":null,"effect":"Osteonecrosis of the jaw (bisphosphonate)"},{"rate":null,"effect":"Atypical fractures (bisphosphonate)"},{"rate":null,"effect":"Ototoxicity (vancomycin)"},{"rate":null,"effect":"Gastrointestinal upset (bisphosphonate)"}]},"_chembl":{"chemblId":"CHEMBL2374170","moleculeType":"Unknown","molecularWeight":"1604.51"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bisphosphonates bind to hydroxyapatite in bone and inhibit osteoclast function, reducing bone resorption and promoting bone formation. Vancomycin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis. The combination aims to simultaneously treat bone infections (via vancomycin) while enhancing bone regeneration and reducing pathological bone loss (via bisphosphonates).","oneSentence":"Bisphosphonates inhibit osteoclast-mediated bone resorption while vancomycin provides antimicrobial coverage, together targeting bone infections and promoting bone healing.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:04:26.269Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bone infections with concurrent bone loss or osteolysis"},{"name":"Osteomyelitis with impaired bone healing"}]},"trialDetails":[{"nctId":"NCT07435051","phase":"PHASE3","title":"Prospective, Randomized, Multicenter Clinical Trial of Bisphosphonates Combined With Vancomycin for the Treatment of Cierny-Mader Type I and III Osteomyelitis","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-05-01","conditions":"Osteomyelitis (Refractory)","enrollment":280}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Bisphosphonates Combined with Vancomycin","genericName":"Bisphosphonates Combined with Vancomycin","companyName":"Second Affiliated Hospital, School of Medicine, Zhejiang University","companyId":"second-affiliated-hospital-school-of-medicine-zhejiang-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bisphosphonates inhibit osteoclast-mediated bone resorption while vancomycin provides antimicrobial coverage, together targeting bone infections and promoting bone healing. Used for Bone infections with concurrent bone loss or osteolysis, Osteomyelitis with impaired bone healing.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}